Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login